Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy

AIDS Patient Care and STDs

Volumn 26, Issue 12, 2012, Pages 714-717

  Westling, Katarina ^a   Pettersson, Karin ^a,b   Kaldma, Anneli ^b   Navér, Lars ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; DETERIORATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL CARE; OUTCOME ASSESSMENT; PRENATAL SCREENING; SINGLE DRUG DOSE; THIRD TRIMESTER PREGNANCY; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BREAST FEEDING; CESAREAN SECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV SEROPOSITIVITY; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PYRROLIDINONES; SWEDEN; TIME FACTORS; VIRAL LOAD;

EID: 84870555946     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0283     Document Type: Article

References (16)

1. Naver L, Albert J, Belfrage E, et al. Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010. Scandinavian Journal of Infectious Diseases. 2011;43:411-423.
2. Naver L, Lindgren S, Belfrage E, et al. Children born to HIV-1-infected women in Sweden in 1982-2003\Trends in epidemiology and vertical transmission. J Acquir Immune Defic Syndr 2006;42:484-489.
3. EACS. Guidelines. Version 6. October 2011. www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6- english.pdf. (Last accessed September 20, 2012).
4. Read PJ, Mandalia S, Khan P, et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 2012;26:1095-103.
5. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. An-tiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006;43:509-515.
6. Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerabil-ity, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008;83:293-299.
7. Clavel C, Peytavin G, Tubiana R, et al. Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study). Antimicrob Agents Chemother 2011;55:3018-3021.
8. McKeown DA, Rosenvinge M, Donaghy S, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010;24: 2416-2418.
9. Croci L, Trezzi M, Allegri MP, et al. Pharmacokinetic and safety of raltegravir in pregnancy. Eur J Clin Pharmacol 2012;68:1231-1232.
10. Taylor N, Touzeau V, Geit M, et al. Raltegravir in pregnancy: A case series presentation. Int J STD AIDS 2011;22: 358-360.
11. Pinnetti C, Baroncelli S, Villani P, et al. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010;65:2050-2052.
12. Jaworsky D, Thompson C, Yudin MH, et al. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: A report of two cases. Antivir Ther 2010;15:677-680.
13. Kreitchmann R, Harris DR, Kakehasi F, et al. Antiretroviral adherence during pregnancy and postpartum in latin america. AIDS Patient Care STDs 2012;26:486-495.
14. Antiretroviral Pregnancy Registry Steering Committee. The Antiretroviral Pregnancy Registry Interim Report for 1 January 1989 through 31 July 2011. Wilmington, N.C.: Registry Coordinating Center, 2011. www.APRegistry.com (Last accessed September 20, 2012).
15. Floridia M, Ravizza M, Guaraldi G, et al.; on behalf of the Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy. Use of specific antiretroviral regimens among HIV-infected women in Italy at time of conception: 2001-2011. AIDS Patient Care STDs 2012;26:439-443.
16. Boer K, England K, Godfried MH, et al. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: Changing practices in Western Europe. HIV Med 2010;11:368-378.